Bangalore-based drugmaker Biocon, is developing its own version of Novo Nordisk's wildly popular weight-loss drug Wegovy in a bid to be a part of the exploding obesity treatment market that is forecast to reach at least $100 billion by 2030. The company's CEO Siddharth Mittal said they aim to be...
India’s Mazumdar-Shaw Raises Goal for Its Bio-Economy for 2025
India's state owned Department of Biotechnology, Ministry of Science & Technology, and the Biotechnology Industry Research Assistance Council (BIRAC) organized the 3rd Global Bio-India 2023, an international congregation on biotechnology, on Dec 4 in New Delhi. The event focused on boosting India's biomanufacturing capabilities through next-gen technologies, biotech innovation, workforce...
India’s Mazumdar-Shaw Establishes Kidney Cancer Initiative at Sloan Kettering
"I am profoundly grateful to Mrs. Mazumdar-Shaw for her generosity and vision in establishing the Mazumdar-Shaw Translational Research Initiative for kidney cancer at Memorial Sloan Kettering Cancer Center (MSK). Your gift has significantly boosted our research programs and will help us expand our decades-long work of leading global clinical studies...
India's Kiran Mazumdar-Shaw Elected to MIT Board
Kiran Mazumdar-Shaw, chairperson and managing director of Bangalore, India-based Biocon, was elected as a full-term member of the MIT Corporation, the Board of Trustees of the Massachusetts Institute of Technology. She is among the eight full-term members who will each serve a term of five years starting July 1, 2018....
51 Indian Pharma Companies Get ANDA Approvals
Fifty-one of the 112 approvals for abbreviated new drug applications (ANDA) given by the USFDA went to India. Further, Indian companies received 6 tentative approvals from an aggregate of 23 tentative approvals in the Jan-March quarter of 2018. With eleven ANDA approvals, Aurobindo Pharma received the highest number among the...
Biocon receives authorization to sell Psoriasis drug in India
Biocon (a Biotechnology Company with headquarters in Bangalore, India) has received the marketing authorization from the Drugs Controller general of India for Novel Biologic Itolizumab (used for the treatment of chronic plaque Psoriasis). Itolizumab has an excellent safety profile as indicated during the 52-week clinical study conducted in India. This...